Medial prefrontal neuroplasticity during extended-release naltrexone treatment of opioid use disorder - a longitudinal structural magnetic resonance imaging study.
Humans
Naltrexone
/ pharmacology
Male
Adult
Female
Magnetic Resonance Imaging
Prefrontal Cortex
/ diagnostic imaging
Delayed-Action Preparations
Narcotic Antagonists
/ pharmacology
Opioid-Related Disorders
/ drug therapy
Neuronal Plasticity
/ drug effects
Positron-Emission Tomography
Longitudinal Studies
Craving
/ drug effects
Gyrus Cinguli
/ diagnostic imaging
Middle Aged
Receptors, Opioid, mu
/ drug effects
Fentanyl
/ administration & dosage
Journal
Translational psychiatry
ISSN: 2158-3188
Titre abrégé: Transl Psychiatry
Pays: United States
ID NLM: 101562664
Informations de publication
Date de publication:
05 Sep 2024
05 Sep 2024
Historique:
received:
09
04
2024
accepted:
22
08
2024
revised:
20
08
2024
medline:
6
9
2024
pubmed:
6
9
2024
entrez:
5
9
2024
Statut:
epublish
Résumé
Opioid use disorder (OUD) has been linked to macroscopic structural alterations in the brain. The monthly injectable, extended-release formulation of μ-opioid antagonist naltrexone (XR-NTX) is highly effective in reducing opioid craving and preventing opioid relapse. Here, we investigated the neuroanatomical effects of XR-NTX by examining changes in cortical thickness during treatment for OUD. Forty-seven OUD patients underwent structural magnetic resonance imaging and subjectively rated their opioid craving ≤1 day before (pre-treatment) and 11 ± 3 days after (on-treatment) the first XR-NTX injection. A sample of fifty-six non-OUD individuals completed a single imaging session and served as the comparison group. A publicly available [¹¹C]carfentanil positron emission tomography dataset was used to assess the relationship between changes in cortical thickness and μ-opioid receptor (MOR) binding potential across brain regions. We found that the thickness of the medial prefrontal and anterior cingulate cortices (mPFC/aCC; regions with high MOR binding potential) was comparable between the non-OUD individuals and the OUD patients at pre-treatment. However, among the OUD patients, mPFC/aCC thickness significantly decreased from pre-treatment to on-treatment. A greater reduction in mPFC/aCC thickness was associated with a greater reduction in opioid craving. Taken together, our study suggests XR-NTX-induced cortical thickness reduction in the mPFC/aCC regions in OUD patients. The reduction in thickness does not appear to indicate a restoration to the non-OUD level but rather reflects XR-NTX's distinct therapeutic impact on an MOR-rich brain structure. Our findings highlight the neuroplastic effects of XR-NTX that may inform the development of novel OUD interventions.
Identifiants
pubmed: 39237534
doi: 10.1038/s41398-024-03061-0
pii: 10.1038/s41398-024-03061-0
doi:
Substances chimiques
Naltrexone
5S6W795CQM
Delayed-Action Preparations
0
Narcotic Antagonists
0
carfentanil
LA9DTA2L8F
Receptors, Opioid, mu
0
Fentanyl
UF599785JZ
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
360Subventions
Organisme : U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA)
ID : K01DA051709
Organisme : U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA)
ID : T32DA028874
Organisme : U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA)
ID : R01DA036028
Organisme : Brain and Behavior Research Foundation (Brain & Behavior Research Foundation)
ID : NARSAD #30780
Organisme : U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (NIAAA)
ID : R00AA026892
Informations de copyright
© 2024. The Author(s).
Références
Bell J, Strang J. Medication treatment of opioid use disorder. Biol Psychiatry. 2020;87:82–8.
pubmed: 31420089
doi: 10.1016/j.biopsych.2019.06.020
Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377:1506–13.
pubmed: 21529928
doi: 10.1016/S0140-6736(11)60358-9
Tanum L, Solli KK, Latif ZE, Benth JŠ, Opheim A, Sharma-Haase K, et al. Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: a randomized clinical noninferiority trial. JAMA Psychiatry. 2017;74:1197–205.
pubmed: 29049469
pmcid: 6583381
doi: 10.1001/jamapsychiatry.2017.3206
Lee JD, Nunes EV Jr, Novo P, Bachrach K, Bailey GL, Bhatt S, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018;391:309–18.
pubmed: 29150198
doi: 10.1016/S0140-6736(17)32812-X
Lee JD, Friedmann PD, Kinlock TW, Nunes EV, Boney TY, Hoskinson RA, et al. Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. N Engl J Med. 2016;374:1232–42.
pubmed: 27028913
pmcid: 5454800
doi: 10.1056/NEJMoa1505409
Sullivan MariaA, Bisaga Adam, Pavlicova Martina, Carpenter KennethM, Choi CJean, Mishlen Kaitlyn, et al. A randomized trial comparing extended-release injectable suspension and oral naltrexone, both combined with behavioral therapy, for the treatment of opioid use disorder. Am J Psychiatry. 2019;176:129–37.
pubmed: 30336703
doi: 10.1176/appi.ajp.2018.17070732
Moningka H, Lichenstein S, Worhunsky PD, DeVito EE, Scheinost D, Yip SW. Can neuroimaging help combat the opioid epidemic? A systematic review of clinical and pharmacological challenge fMRI studies with recommendations for future research. Neuropsychopharmacology. 2019;44:259–73.
pubmed: 30283002
doi: 10.1038/s41386-018-0232-4
Pollard AA, Hauson AO, Lackey NS, Zhang E, Khayat S, Carson B, et al. Functional neuroanatomy of craving in heroin use disorder: voxel-based meta-analysis of functional magnetic resonance imaging (fMRI) drug cue reactivity studies. Am J Drug Alcohol Abuse. 2023;49:418–30.
pubmed: 36880845
doi: 10.1080/00952990.2023.2172423
Li Q, Wang Y, Zhang Y, Li W, Yang W, Zhu J, et al. Craving correlates with mesolimbic responses to heroin-related cues in short-term abstinence from heroin: an event-related fMRI study. Brain Res. 2012;1469:63–72.
pubmed: 22759909
doi: 10.1016/j.brainres.2012.06.024
Li Q, Li W, Wang H, Wang Y, Zhang Y, Zhu J, et al. Predicting subsequent relapse by drug-related cue-induced brain activation in heroin addiction: an event-related functional magnetic resonance imaging study. Addict Biol. 2015;20:968–78.
pubmed: 25214465
doi: 10.1111/adb.12182
Madden GJ, Petry NM, Badger GJ, Bickel WK. Impulsive and self-control choices in opioid-dependent patients and non-drug-using control patients: drug and monetary rewards. Exp Clin Psychopharmacol. 1997;5:256–62.
pubmed: 9260073
doi: 10.1037/1064-1297.5.3.256
Lee TMC, Pau CWH. Impulse control differences between abstinent heroin users and matched controls. Brain Inj. 2002;16:885–89.
pubmed: 12419001
doi: 10.1080/02699050210128915
Zeng H, Lee TMC, Waters JH, So K-F, Sham PC, Schottenfeld RS, et al. Impulsivity, cognitive function, and their relationship in heroin-dependent individuals. J Clin Exp Neuropsychol. 2013;35:897–905.
pubmed: 24040894
doi: 10.1080/13803395.2013.828022
Fu L-p, Bi G-h, Zou Z-t, Wang Y, Ye E-m, Ma L, et al. Impaired response inhibition function in abstinent heroin dependents: an fMRI study. Neurosci Lett. 2008;438:322–26.
pubmed: 18485592
doi: 10.1016/j.neulet.2008.04.033
Yang B, Yang S, Zhao L, Yin L, Liu X, An S. Event-related potentials in a Go/Nogo task of abnormal response inhibition in heroin addicts. Sci China Ser C: Life Sci. 2009;52:780–88.
doi: 10.1007/s11427-009-0106-4
Ceceli AO, King SG, McClain N, Alia-Klein N, Goldstein RZ. The neural signature of impaired inhibitory control in individuals with heroin use disorder. J Neurosci. 2023;43:173–82.
pubmed: 36396402
pmcid: 9838696
doi: 10.1523/JNEUROSCI.1237-22.2022
Li Q, Wang Y, Zhang Y, Li W, Zhu J, Zheng Y, et al. Assessing cue-induced brain response as a function of abstinence duration in heroin-dependent individuals: an event-related fMRI study. PLoS One. 2013;8:e62911.
pubmed: 23667541
pmcid: 3646913
doi: 10.1371/journal.pone.0062911
Langleben DD, Ruparel K, Elman I, Busch-Winokur S, Pratiwadi R, Loughead J, et al. Acute effect of methadone maintenance dose on brain fmri response to heroin-related cues. Am J Psychiatry. 2008;165:390–4.
pubmed: 18056224
doi: 10.1176/appi.ajp.2007.07010070
Langleben DD, Ruparel K, Elman I, Loughead JW, Busch EL, Cornish J, et al. Extended-release naltrexone modulates brain response to drug cues in abstinent heroin-dependent patients. Addict Biol. 2014;19:262–71.
pubmed: 22747521
doi: 10.1111/j.1369-1600.2012.00462.x
Shi Z, Wang A-L, Jagannathan K, Fairchild VP, O’Brien CP, Childress AR, et al. Effects of extended-release naltrexone on the brain response to drug-related stimuli in patients with opioid use disorder. J Psychiatry Neurosci. 2018;43:254–61.
pubmed: 29947607
pmcid: 6019353
doi: 10.1503/jpn.170036
Yang L, Xu Q, Li S, Zhao X, Ma L, Zheng Y, et al. The effects of methadone maintenance treatment on heroin addicts with response inhibition function impairments: evidence from event-related potentials. J Food Drug Anal. 2015;23:260–66.
pubmed: 28911381
doi: 10.1016/j.jfda.2014.06.002
Kriegler J, Wegener S, Richter F, Scherbaum N, Brand M, Wegmann E. Decision making of individuals with heroin addiction receiving opioid maintenance treatment compared to early abstinent users. Drug Alcohol Depend. 2019;205:107593.
pubmed: 31634665
doi: 10.1016/j.drugalcdep.2019.107593
Yang T, Zhao X, Zhang F, Li X, Zhu H, Zhang M, et al. Craving-induced effects of different drug cues on persons abstaining from heroin. Addict Res Theory. 2019;27:235–41.
doi: 10.1080/16066359.2018.1496425
Tolomeo S, Gray S, Matthews K, Steele JD, Baldacchino A. Multifaceted impairments in impulsivity and brain structural abnormalities in opioid dependence and abstinence. Psychol Med. 2016;46:2841–53.
pubmed: 27452238
doi: 10.1017/S0033291716001513
Biernacki K, McLennan SN, Terrett G, Labuschagne I, Rendell PG. Decision-making ability in current and past users of opiates: a meta-analysis. Neurosci Biobehav Rev. 2016;71:342–51.
pubmed: 27649645
doi: 10.1016/j.neubiorev.2016.09.011
Wang X, Li B, Zhou X, Liao Y, Tang J, Liu T, et al. Changes in brain gray matter in abstinent heroin addicts. Drug Alcohol Depend. 2012;126:304–08.
pubmed: 22717339
doi: 10.1016/j.drugalcdep.2012.05.030
Ieong HF-H, Yuan Z. Resting-state neuroimaging and neuropsychological findings in opioid use disorder during abstinence: a review. Front Hum Neurosci. 2017;11:169.
pubmed: 28428748
pmcid: 5382168
doi: 10.3389/fnhum.2017.00169
Liu J, Liang J, Qin W, Tian J, Yuan K, Bai L, et al. Dysfunctional connectivity patterns in chronic heroin users: an fMRI study. Neurosci Lett. 2009;460:72–7.
pubmed: 19450664
doi: 10.1016/j.neulet.2009.05.038
Li M, Tian J, Zhang R, Qiu Y, Wen X, Ma X, et al. Abnormal cortical thickness in heroin-dependent individuals. Neuroimage. 2014;88:295–307.
pubmed: 24140937
doi: 10.1016/j.neuroimage.2013.10.021
Wollman SC, Alhassoon OM, Hall MG, Stern MJ, Connors EJ, Kimmel CL, et al. Gray matter abnormalities in opioid-dependent patients: a neuroimaging meta-analysis. Am J Drug Alcohol Abuse. 2017;43:505–17.
pubmed: 27808568
doi: 10.1080/00952990.2016.1245312
Shi Z, Li X, Byanyima JI, O’Brien CP, Childress AR, Lynch KG, et al. Effects of current smoking severity on brain gray matter volume in opioid use disorder–a voxel-based morphometry study. Am J Drug Alcohol Abuse. 2023;49:180–89.
pubmed: 36787540
pmcid: 10164057
doi: 10.1080/00952990.2023.2169616
Hutton C, Draganski B, Ashburner J, Weiskopf N. A comparison between voxel-based cortical thickness and voxel-based morphometry in normal aging. Neuroimage. 2009;48:371–80.
pubmed: 19559801
doi: 10.1016/j.neuroimage.2009.06.043
Winkler AM, Kochunov P, Blangero J, Almasy L, Zilles K, Fox PT, et al. Cortical thickness or grey matter volume? The importance of selecting the phenotype for imaging genetics studies. Neuroimage. 2010;53:1135–46.
pubmed: 20006715
doi: 10.1016/j.neuroimage.2009.12.028
Tustison NJ, Cook PA, Klein A, Song G, Das SR, Duda JT, et al. Large-scale evaluation of ANTs and FreeSurfer cortical thickness measurements. Neuroimage. 2014;99:166–79.
pubmed: 24879923
doi: 10.1016/j.neuroimage.2014.05.044
Yang W, Zhang M, Tang F, Du Y, Fan L, Luo J, et al. Recovery of superior frontal gyrus cortical thickness and resting-state functional connectivity in abstinent heroin users after 8 months of follow-up. Hum Brain Mapp. 2022;43:3164–75.
pubmed: 35324057
pmcid: 9188969
doi: 10.1002/hbm.25841
Schmidt A, Vogel M, Baumgartner S, Wiesbeck GA, Lang U, Borgwardt S, et al. Brain volume changes after long-term injectable opioid treatment: a longitudinal voxel-based morphometry study. Addict Biol. 2021;26:e12970.
pubmed: 33000891
doi: 10.1111/adb.12970
Zhu J, Wang S, Liu Y, Wang F, Li Q, Li Z, et al. The influence of methadone on cerebral gray matter and functional connectivity. Annals of Palliative Medicine. 2021;10:9497–507.
pubmed: 34628875
doi: 10.21037/apm-21-2012
Kantonen T, Karjalainen T, Isojärvi J, Nuutila P, Tuisku J, Rinne J, et al. Interindividual variability and lateralization of μ-opioid receptors in the human brain. Neuroimage. 2020;217:116922.
pubmed: 32407992
doi: 10.1016/j.neuroimage.2020.116922
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatr. 1998;59:22–33.
Paronis CA, Bergman J. Buprenorphine and opioid antagonism, tolerance, and naltrexone-precipitated withdrawal. J Pharmacol Exp Ther. 2011;336:488–95.
pubmed: 21051498
pmcid: 3033719
doi: 10.1124/jpet.110.173823
Ruan X, Chen T, Gudin J, Couch JP, Chiravuri S. Acute opioid withdrawal precipitated by ingestion of crushed embeda (morphine extended release with sequestered naltrexone): case report and the focused review of the literature. J Opioid Manag. 2010;6:300–03.
pubmed: 20862910
doi: 10.5055/jom.2010.0028
Slawson MH, Chen M, Moody D, Comer SD, Nuwayser ES, Fang WB, et al. Quantitative analysis of naltrexone and 6β-naltrexol in human, rat, and rabbit plasma by liquid chromatography-electrospray ionization tandem mass spectrometry with application to the pharmacokinetics of Depotrex® in rabbits. J Anal Toxicol. 2007;31:453–61.
pubmed: 17988459
doi: 10.1093/jat/31.8.453
Dunbar JL, Turncliff RZ, Dong Q, Silverman BL, Ehrich EW, Lasseter KC. Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone. Alcoholism: Clinical and Experimental Research. 2006;30:480–90.
pubmed: 16499489
doi: 10.1111/j.1530-0277.2006.00052.x
Tustison NJ, Cook PA, Holbrook AJ, Johnson HJ, Muschelli J, Devenyi GA et al. The ANTsX ecosystem for quantitative biological and medical imaging. Sci Rep. 2021;11:9068. https://doi.org/10.1038/s41598-021-87564-6 .
Tustison NJ, Avants BB, Cook PA, Zheng Y, Egan A, Yushkevich PA, et al. N4ITK: improved N3 bias correction. IEEE Trans Med Imaging. 2010;29:1310–20.
pubmed: 20378467
pmcid: 3071855
doi: 10.1109/TMI.2010.2046908
Avants BB, Tustison NJ, Wu J, Cook PA, Gee JC. An open source multivariate framework for n-tissue segmentation with evaluation on public data. Neuroinformatics. 2011;9:381–400.
pubmed: 21373993
pmcid: 3297199
doi: 10.1007/s12021-011-9109-y
Das SR, Avants BB, Grossman M, Gee JC. Registration based cortical thickness measurement. Neuroimage. 2009;45:867–79.
pubmed: 19150502
doi: 10.1016/j.neuroimage.2008.12.016
Smith SM, Nichols TE. Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference. Neuroimage. 2009;44:83–98.
pubmed: 18501637
doi: 10.1016/j.neuroimage.2008.03.061
Glasser MF, Coalson TS, Robinson EC, Hacker CD, Harwell J, Yacoub E, et al. A multi-modal parcellation of human cerebral cortex. Nature. 2016;536:171–78.
pubmed: 27437579
pmcid: 4990127
doi: 10.1038/nature18933
Wang A-L, Shi Z, Elman I, Langleben DD. Reduced cigarette smoking during injectable extended-release naltrexone treatment for opioid use disorder. Am J Drug Alcohol Abuse. 2020;46:472–77.
pubmed: 32379516
doi: 10.1080/00952990.2020.1741001
Fischl B, Dale AM. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci USA 2000;97:11050–55.
pubmed: 10984517
pmcid: 27146
doi: 10.1073/pnas.200033797
Wagstyl K, Lerch JP. Cortical thickness. In: Spalletta G, Piras F, Gili T, editors. Brain Morphometry. New York, NY: Springer; 2018. p. 35–49.
la Fougère C, Grant S, Kostikov A, Schirrmacher R, Gravel P, Schipper HM, et al. Where in-vivo imaging meets cytoarchitectonics: the relationship between cortical thickness and neuronal density measured with high-resolution [18F]flumazenil-PET. Neuroimage. 2011;56:951–60.
pubmed: 21073964
doi: 10.1016/j.neuroimage.2010.11.015
Bennett MR. Schizophrenia: susceptibility genes, dendritic-spine pathology and gray matter loss. Prog Neurobiol. 2011;95:275–300.
pubmed: 21907759
doi: 10.1016/j.pneurobio.2011.08.003
Russell TA, Blizinsky KD, Cobia DJ, Cahill ME, Xie Z, Sweet RA, et al. A sequence variant in human KALRN impairs protein function and coincides with reduced cortical thickness. Nature Communications. 2014;5:4858.
pubmed: 25224588
doi: 10.1038/ncomms5858
Carlo CN, Stevens CF. Structural uniformity of neocortex, revisited. Proc Natl Acad Sci USA 2013;110:1488–93.
pubmed: 23297199
pmcid: 3557031
doi: 10.1073/pnas.1221398110
Vidal-Pineiro D, Parker N, Shin J, French L, Grydeland H, Jackowski AP, et al. Cellular correlates of cortical thinning throughout the lifespan. Sci Rep. 2020;10:21803.
pubmed: 33311571
pmcid: 7732849
doi: 10.1038/s41598-020-78471-3
Shin J, French L, Xu T, Leonard G, Perron M, Pike GB, et al. Cell-specific gene-expression profiles and cortical thickness in the human brain. Cereb Cortex. 2017;28:3267–77.
doi: 10.1093/cercor/bhx197
Writing Committee for the Attention-Deficit/Hyperactivity Disorder, Autism Spectrum Disorder, Bipolar Disorder, Major Depressive Disorder, Obsessive-Compulsive Disorder, and Schizophrenia ENIGMA Working Groups. Virtual histology of cortical thickness and shared neurobiology in 6 psychiatric disorders. JAMA Psychiatry. 2021;78:47–63.
Hauser KF, McLaughlin PJ, Zagon IS. Endogenous opioid systems and the regulation of dendritic growth and spine formation. J Comp Neurol. 1989;281:13–22.
pubmed: 2925898
doi: 10.1002/cne.902810103
Liao D, Lin H, Law PY, Loh HH. Mu-opioid receptors modulate the stability of dendritic spines. Proc Natl Acad Sci USA 2005;102:1725–30.
pubmed: 15659552
pmcid: 545084
doi: 10.1073/pnas.0406797102
Ricalde AA, Hammer RP. Perinatal opiate treatment delays growth of cortical dendrites. Neurosci Lett. 1990;115:137–43.
pubmed: 2172870
doi: 10.1016/0304-3940(90)90444-E
Liu SX, Gades MS, Swain Y, Ramakrishnan A, Harris AC, Tran PV, et al. Repeated morphine exposure activates synaptogenesis and other neuroplasticity-related gene networks in the dorsomedial prefrontal cortex of male and female rats. Drug Alcohol Depend. 2021;221:108598.
pubmed: 33626484
pmcid: 8026706
doi: 10.1016/j.drugalcdep.2021.108598
Bansal R, Hellerstein DJ, Peterson BS. Evidence for neuroplastic compensation in the cerebral cortex of persons with depressive illness. Mol Psychiatry. 2018;23:375–83.
pubmed: 28265119
doi: 10.1038/mp.2017.34
Thambisetty M, Wan J, Carass A, An Y, Prince JL, Resnick SM. Longitudinal changes in cortical thickness associated with normal aging. Neuroimage. 2010;52:1215–23.
pubmed: 20441796
doi: 10.1016/j.neuroimage.2010.04.258
Apostolova LG, Thompson PM. Brain mapping as a tool to study neurodegeneration. Neurotherapeutics. 2007;4:387–400.
pubmed: 17599704
pmcid: 2634605
doi: 10.1016/j.nurt.2007.05.009
Govindarajan KA, Narayana PA, Hasan KM, Wilde EA, Levin HS, Hunter JV, et al. Cortical thickness in mild traumatic brain injury. J Neurotrauma. 2016;33:1809–17.
pubmed: 26959810
pmcid: 5079411
doi: 10.1089/neu.2015.4253
Schmaal L, Hibar DP, Sämann PG, Hall GB, Baune BT, Jahanshad N, et al. Cortical abnormalities in adults and adolescents with major depression based on brain scans from 20 cohorts worldwide in the ENIGMA Major Depressive Disorder Working Group. Mol Psychiatry. 2017;22:900–09.
pubmed: 27137745
doi: 10.1038/mp.2016.60
Zhu Z, Zhao Y, Wen K, Li Q, Pan N, Fu S, et al. Cortical thickness abnormalities in patients with bipolar disorder: a systematic review and meta-analysis. J Affect Disord. 2022;300:209–18.
pubmed: 34971699
doi: 10.1016/j.jad.2021.12.080
Fouche J-P, du Plessis S, Hattingh C, Roos A, Lochner C, Soriano-Mas C, et al. Cortical thickness in obsessive–compulsive disorder: multisite mega-analysis of 780 brain scans from six centres. Br J Psychiatry. 2017;210:67–74.
pubmed: 27198485
doi: 10.1192/bjp.bp.115.164020
Zhao Y, Zhang Q, Shah C, Li Q, Sweeney JA, Li F, et al. Cortical thickness abnormalities at different stages of the illness course in schizophrenia: a systematic review and meta-analysis. JAMA Psychiatry. 2022;79:560–70.
pubmed: 35476125
pmcid: 9047772
doi: 10.1001/jamapsychiatry.2022.0799
Li L, Zhang Y, Zhao Y, Li Z, Kemp GJ, Wu M, et al. Cortical thickness abnormalities in patients with post-traumatic stress disorder: a vertex-based meta-analysis. Neurosci Biobehav Rev. 2022;134:104519.
pubmed: 34979190
doi: 10.1016/j.neubiorev.2021.104519
Yuan P, Raz N. Prefrontal cortex and executive functions in healthy adults: a meta-analysis of structural neuroimaging studies. Neurosci Biobehav Rev. 2014;42:180–92.
pubmed: 24568942
doi: 10.1016/j.neubiorev.2014.02.005
Krupitsky E, Nunes EV, Ling W, Gastfriend DR, Memisoglu A, Silverman BL. Injectable extended‐release naltrexone (XR‐NTX) for opioid dependence: long‐term safety and effectiveness. Addiction. 2013;108:1628–37.
pubmed: 23701526
doi: 10.1111/add.12208
Solli KK, Latif ZeH, Opheim A, Krajci P, Sharma‐Haase K, Benth JŠ, et al. Effectiveness, safety and feasibility of extended‐release naltrexone for opioid dependence: a 9‐month follow‐up to a 3‐month randomized trial. Addiction. 2018;113:1840–49.
pubmed: 29806872
doi: 10.1111/add.14278
Rodefer JS, Nguyen TN. Naltrexone reverses age-induced cognitive deficits in rats. Neurobiol Aging. 2008;29:309–13.
pubmed: 17098330
doi: 10.1016/j.neurobiolaging.2006.10.005
Grant JE, Odlaug BL, Schreiber LR, Kim SW. The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. J Clin Psychopharmacol. 2014;34:134–38.
pubmed: 24145220
doi: 10.1097/JCP.0000000000000037
van Steenbergen H, Weissman DH, Stein DJ, Malcolm-Smith S, van Honk J. More pain, more gain: blocking the opioid system boosts adaptive cognitive control. Psychoneuroendocrinology. 2017;80:99–103.
pubmed: 28324705
doi: 10.1016/j.psyneuen.2017.03.002
Maartje L, Marise WJM, Dick JV, Robert H, Lieuwe de H, Ingmar HAF. Systematic review of ERP and fMRI studies investigating inhibitory control and error processing in people with substance dependence and behavioural addictions. J Psychiatry Neurosci. 2014;39:149–69.
doi: 10.1503/jpn.130052
Rushworth MatthewFS, Noonan MaryAnnP, Boorman ErieD, Walton MarkE, Behrens TimothyE. Frontal cortex and reward-guided learning and decision-making. Neuron. 2011;70:1054–69.
pubmed: 21689594
doi: 10.1016/j.neuron.2011.05.014
Schulte MHJ, Cousijn J, den Uyl TE, Goudriaan AE, van den Brink W, Veltman DJ, et al. Recovery of neurocognitive functions following sustained abstinence after substance dependence and implications for treatment. Clin Psychol Rev. 2014;34:531–50.
pubmed: 25240109
doi: 10.1016/j.cpr.2014.08.002
Guerra D, Solé A, Camí J, Tobeña A. Neuropsychological performance in opiate addicts after rapid detoxification. Drug Alcohol Depend. 1987;20:261–70.
pubmed: 3436258
doi: 10.1016/0376-8716(87)90036-6
Kaur G, Sidana A, Singh S, Gupta A. Effects of abstinence from opioid on neuropsychological performance in men with opioid use disorder: a longitudinal study. J Addict Med. 2023;17:557–62.
pubmed: 37788609
doi: 10.1097/ADM.0000000000001177
Wollman SC, Hauson AO, Hall MG, Connors EJ, Allen KE, Stern MJ, et al. Neuropsychological functioning in opioid use disorder: a research synthesis and meta-analysis. Am J Drug Alcohol Abuse. 2019;45:11–25.
pubmed: 30359116
doi: 10.1080/00952990.2018.1517262
Garland EL. Restructuring reward processing with Mindfulness-Oriented Recovery Enhancement: novel therapeutic mechanisms to remediate hedonic dysregulation in addiction, stress, and pain. Ann N Y Acad Sci. 2016;1373:25–37.
pubmed: 27037786
pmcid: 4940274
doi: 10.1111/nyas.13034
Verdejo-Garcia A. Cognitive training for substance use disorders: neuroscientific mechanisms. Neurosci Biobehav Rev. 2016;68:270–81.
pubmed: 27236041
doi: 10.1016/j.neubiorev.2016.05.018
Valls-Serrano C, Caracuel A, Verdejo-Garcia A. Goal Management Training and Mindfulness Meditation improve executive functions and transfer to ecological tasks of daily life in polysubstance users enrolled in therapeutic community treatment. Drug Alcohol Depend. 2016;165:9–14.
pubmed: 27246405
doi: 10.1016/j.drugalcdep.2016.04.040
Sofuoglu M. Cognitive enhancement as a pharmacotherapy target for stimulant addiction. Addiction. 2010;105:38–48.
pubmed: 20078461
pmcid: 2808705
doi: 10.1111/j.1360-0443.2009.02791.x
Scott TM, Rivera Mindt M, Cunningham CO, Arias F, Coulehan K, Mangalonzo A, et al. Neuropsychological function is improved among opioid dependent adults who adhere to opiate agonist treatment with buprenorphine-naloxone: a preliminary study. Subst Abuse Treat Prev Policy. 2017;12:48.
pubmed: 29141650
pmcid: 5688712
doi: 10.1186/s13011-017-0133-2
Kosten T, Aharonovich E, Nangia N, Zavod A, Akerman SC, Lopez-Bresnahan M, et al. Cognitive performance of patients with opioid use disorder transitioned to extended-release injectable naltrexone from buprenorphine: post hoc analysis of exploratory results of a phase 3 randomized controlled trial. Addict Behav. 2020;111:106538.
pubmed: 32777606
doi: 10.1016/j.addbeh.2020.106538
Tost H, Braus DF, Hakimi S, Ruf M, Vollmert C, Hohn F, et al. Acute D2 receptor blockade induces rapid, reversible remodeling in human cortical-striatal circuits. Nat Neurosci. 2010;13:920–22.
pubmed: 20526332
doi: 10.1038/nn.2572
Fusar-Poli P, Smieskova R, Kempton MJ, Ho BC, Andreasen NC, Borgwardt S. Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. Neurosci Biobehav Rev. 2013;37:1680–91.
pubmed: 23769814
pmcid: 3964856
doi: 10.1016/j.neubiorev.2013.06.001
Ansell BRE, Dwyer DB, Wood SJ, Bora E, Brewer WJ, Proffitt TM, et al. Divergent effects of first-generation and second-generation antipsychotics on cortical thickness in first-episode psychosis. Psychol Med. 2015;45:515–27.
pubmed: 25077698
doi: 10.1017/S0033291714001652
Mattson MP. Neurotransmitters in the regulation of neuronal cytoarchitecture. Brain Res Rev. 1988;13:179–212.
doi: 10.1016/0165-0173(88)90020-3
MacDonald SWS, Nyberg L, Bäckman L. Intra-individual variability in behavior: links to brain structure, neurotransmission and neuronal activity. Trends Neurosci. 2006;29:474–80.
pubmed: 16820224
doi: 10.1016/j.tins.2006.06.011
Hansen JY, Shafiei G, Markello RD, Smart K, Cox SML, Nørgaard M, et al. Mapping neurotransmitter systems to the structural and functional organization of the human neocortex. Nat Neurosci. 2022;25:1569–81.
pubmed: 36303070
pmcid: 9630096
doi: 10.1038/s41593-022-01186-3
Bartels A, Zeki S. The neural basis of romantic love. Neuroreport. 2000;11:3829–34.
pubmed: 11117499
doi: 10.1097/00001756-200011270-00046
Knutson B, Fong GW, Bennett SM, Adams CM, Hommer D. A region of mesial prefrontal cortex tracks monetarily rewarding outcomes: characterization with rapid event-related fMRI. Neuroimage. 2003;18:263–72.
pubmed: 12595181
doi: 10.1016/S1053-8119(02)00057-5
McClure SM, Li J, Tomlin D, Cypert KS, Montague LM, Montague PR. Neural correlates of behavioral preference for culturally familiar drinks. Neuron. 2004;44:379–87.
pubmed: 15473974
doi: 10.1016/j.neuron.2004.09.019
Kühn S, Gallinat J. Common biology of craving across legal and illegal drugs - a quantitative meta-analysis of cue-reactivity brain response. Eur J Neurosci. 2011;33:1318–26.
pubmed: 21261758
doi: 10.1111/j.1460-9568.2010.07590.x
Kober H, Lacadie CM, Wexler BE, Malison RT, Sinha R, Potenza MN. Brain activity during cocaine craving and gambling urges: an fMRI study. Neuropsychopharmacology. 2016;41:628–37.
pubmed: 26119472
doi: 10.1038/npp.2015.193
Koban L, Wager TD, Kober H. A neuromarker for drug and food craving distinguishes drug users from non-users. Nat Neurosci. 2023;26:316–25.
pubmed: 36536243
doi: 10.1038/s41593-022-01228-w
Sullivan MA, Bisaga A, Mariani JJ, Glass A, Levin FR, Comer SD, et al. Naltrexone treatment for opioid dependence: does its effectiveness depend on testing the blockade? Drug Alcohol Depend. 2013;133:80–5.
pubmed: 23827259
pmcid: 3955093
doi: 10.1016/j.drugalcdep.2013.05.030
Hampton AN, O’Doherty JP. Decoding the neural substrates of reward-related decision making with functional MRI. Proc Natl Acad Sci USA 2007;104:1377–82.
pubmed: 17227855
pmcid: 1783089
doi: 10.1073/pnas.0606297104
Van Overwalle F. Social cognition and the brain: a meta-analysis. Hum Brain Mapp. 2009;30:829–58.
pubmed: 18381770
doi: 10.1002/hbm.20547
Volkow ND. The epidemic of fentanyl misuse and overdoses: challenges and strategies. World Psychiatry. 2021;20:195–96.
pubmed: 34002497
pmcid: 8129846
doi: 10.1002/wps.20846
Ching JH, Owens DK, Trafton JA, Goldhaber-Fiebert JD, Salomon JA. Impact of treatment duration on mortality among Veterans with opioid use disorder in the United States Veterans Health Administration. Addiction. 2021;116:3494–503.
pubmed: 33999485
pmcid: 8578188
doi: 10.1111/add.15574